For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Avidity Biosciences Inc’s stock clocked out at $71.7, up 0.20% from its previous closing price of $71.56. In other words, the price has increased by $0.20 from its previous closing price. On the day, 1.07 million shares were traded. RNA stock price reached its highest trading level at $71.78 during the session, while it also had its lowest trading level at $71.57.
Ratios:
To gain a deeper understanding of RNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.57 and its Current Ratio is at 11.57. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In the most recent recommendation for this company, Roth Capital on September 17, 2025, initiated with a Buy rating and assigned the stock a target price of $62.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 22 ’25 when Hughes Steven George sold 2,209 shares for $47.54 per share. The transaction valued at 105,015 led to the insider holds 38,867 shares of the business.
McCarthy Teresa sold 20,000 shares of RNA for $1,003,058 on Oct 15 ’25. The Chief Human Resources Officer now owns 97,130 shares after completing the transaction at $50.15 per share. On Oct 03 ’25, another insider, Mosbrooker Eric, who serves as the Chief Commercial Officer of the company, sold 6,562 shares for $45.38 each. As a result, the insider received 297,771 and left with 55,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 10803450880 and an Enterprise Value of 8977581056. For the stock, the TTM Price-to-Sale (P/S) ratio is 517.65 while its Price-to-Book (P/B) ratio in mrq is 5.58. Its current Enterprise Value per Revenue stands at 430.208 whereas that against EBITDA is -14.74.
Stock Price History:
The Beta on a monthly basis for RNA is 0.90, which has changed by 0.7360774 over the last 52 weeks, in comparison to a change of 0.1326145 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $71.75, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 23.93%, while the 200-Day Moving Average is calculated to be 79.63%.
Shares Statistics:
It appears that RNA traded 5.22M shares on average per day over the past three months and 2670960 shares per day over the past ten days. A total of 146.77M shares are outstanding, with a floating share count of 138.12M. Insiders hold about 8.29% of the company’s shares, while institutions hold 99.76% stake in the company. Shares short for RNA as of 1763078400 were 10321719 with a Short Ratio of 1.98, compared to 1760486400 on 20028193. Therefore, it implies a Short% of Shares Outstanding of 10321719 and a Short% of Float of 6.9.
Earnings Estimates
Avidity Biosciences Inc (RNA) is currently under the scrutiny of 10.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$1.28, with high estimates of -$0.98 and low estimates of -$1.59.
Analysts are recommending an EPS of between -$3.62 and -$5.16 for the fiscal current year, implying an average EPS of -$4.49. EPS for the following year is -$4.9, with 14.0 analysts recommending between -$3.24 and -$6.53.
Revenue Estimates
In . The current quarter, 13 analysts expect revenue to total $1.98M. It ranges from a high estimate of $12.5M to a low estimate of -$6.5M. As of . The current estimate, Avidity Biosciences Inc’s year-ago sales were $2.97M
A total of 11 analysts have provided revenue estimates for RNA’s current fiscal year. The highest revenue estimate was $30.4M, while the lowest revenue estimate was $11.4M, resulting in an average revenue estimate of $20.33M. In the same quarter a year ago, actual revenue was $10.9M
